Haleon (HLN) Common Equity (2021 - 2025)
Haleon (HLN) posted Common Equity of $21.9 billion for Q4 2025, up 5.3% on a QoQ basis from $20.8 billion in Q4 2024, and up 5.3% year-over-year from $20.8 billion in Q4 2024.
Haleon (HLN) Common Equity (2021 - 2025) Analysis & Trends
Haleon's Common Equity history runs 5 years deep, the most recent figure standing at $21.9 billion for Q4 2025.
- Quarterly Common Equity rose 5.3% year-over-year to $21.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.9 billion (up 5.3% YoY) and the FY2025 annual result came in at $21.7 billion, up 4.8% from the prior year.
- Common Equity was $21.9 billion for Q4 2025 at Haleon, up from $20.8 billion in the prior quarter.
- Across five years, Common Equity topped out at $35.7 billion in Q4 2021 and bottomed at $19.3 billion in Q4 2022.
- A 5-year average of $24.3 billion and a median of $21.0 billion in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity sank 45.92% — and 2023, when it climbed 7.57%.
- Haleon's Common Equity stood at $35.7 billion in 2021, then sank by 45.92% to $19.3 billion in 2022, then rose by 7.57% to $20.8 billion in 2023, then increased by 0.29% to $20.8 billion in 2024, then rose by 5.3% to $21.9 billion in 2025.
- Business Quant data shows HLN's Common Equity at $21.9 billion in Q4 2025, $20.8 billion in Q4 2024, and $21.1 billion in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 5.90 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 4.27 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 294.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.93 Bn |
| Dec 31, 2024 | 20.82 Bn |
| Jun 30, 2024 | 21.09 Bn |
| Dec 31, 2023 | 20.76 Bn |
| Jun 30, 2023 | 20.73 Bn |
| Dec 31, 2022 | 19.30 Bn |
| Jun 30, 2022 | 34.00 Bn |
| Dec 31, 2021 | 35.70 Bn |